BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35051553)

  • 1. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
    Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
    Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FMO1 Promotes Nonalcoholic Fatty Liver Disease Progression by Regulating PPARα Activation and Inducing Ferroptosis.
    Zou L; Shi Q; Li Y; Yuan Z; Peng L; Lu J; Zhu H; Ma J
    Discov Med; 2023 Aug; 35(177):612-622. PubMed ID: 37553313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
    Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRDX6 Promotes Fatty Acid Oxidation
    Shen W; Yang L; Yang Y; Wang P; Tao X; Shen Y; Wang S; Shen Y
    Antioxid Redox Signal; 2023 Jun; 38(16-18):1184-1200. PubMed ID: 36401357
    [No Abstract]   [Full Text] [Related]  

  • 5. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
    Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
    Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
    Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
    J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
    Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
    Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD
    Xie L; Wen K; Li Q; Huang CC; Zhao JL; Zhao QH; Xiao YF; Guan XH; Qian YS; Gan L; Wang LF; Deng KY; Xin HB
    Int J Biol Sci; 2021; 17(15):4305-4315. PubMed ID: 34803499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferulic Acid Prevents Nonalcoholic Fatty Liver Disease by Promoting Fatty Acid Oxidation and Energy Expenditure in C57BL/6 Mice Fed a High-Fat Diet.
    Luo Z; Li M; Yang Q; Zhang Y; Liu F; Gong L; Han L; Wang M
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK/SREBP-1c/PPARα pathway.
    Liu X; Hu M; Ye C; Liao L; Ding C; Sun L; Liang J; Chen Y
    Chem Biol Interact; 2022 Dec; 368():110250. PubMed ID: 36347319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
    Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
    J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.
    Régnier M; Polizzi A; Smati S; Lukowicz C; Fougerat A; Lippi Y; Fouché E; Lasserre F; Naylies C; Bétoulières C; Barquissau V; Mouisel E; Bertrand-Michel J; Batut A; Saati TA; Canlet C; Tremblay-Franco M; Ellero-Simatos S; Langin D; Postic C; Wahli W; Loiseau N; Guillou H; Montagner A
    Sci Rep; 2020 Apr; 10(1):6489. PubMed ID: 32300166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fat mass and obesity-associated protein promotes liver steatosis by targeting PPARα.
    Wei X; Zhang J; Tang M; Wang X; Fan N; Peng Y
    Lipids Health Dis; 2022 Mar; 21(1):29. PubMed ID: 35282837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
    Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
    J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.